Combating Inflammation in Cardiovascular Disease

被引：40

作者：

Sethwala, Anver M. ^{[1
]}

Goh, Ian ^{[1
]}

Amerena, John, V ^{[1
]}

机构：

[1] Univ Hosp Geelong, Dept Cardiol, Barwon Hlth, Geelong, Vic, Australia

来源：

HEART LUNG AND CIRCULATION | 2021年 / 30卷 / 02期

关键词：

Inflammation; Cardiovascular disease; High-sensitivity C-reactive protein;

D O I：

10.1016/j.hlc.2020.09.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The role of inflammation in promoting atherosclerosis and subsequent cardiovascular disease is increasingly recognised, particularly after the publication of Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS) and Colchicine Cardiovascular Outcomes (COLCOT) trials. It appears that specifically targeting the Nod-like receptor protein 3 (NLRP3) inflammasome-interleukin 1/interleukin 18-interleukin 6 pathway appears to be most beneficial in cardiovascular risk reduction. High sensitivity C-reactive protein (CRP) is a downstream biomarker of inflammation that can be used to monitor treatment. This article will discuss the role of inflammation in cardiovascular disease, the utility of high sensitivity C-reactive protein and treatments that target this inflammation. While further research is needed into the cost effectiveness and safety of newer agents, it remains an evolving approach to manage cardiovascular risk.

引用

页码：197 / 206

页数：10

共 83 条

[1] Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease [J].

Aday, Aaron W. ;

Ridker, Paul M. .

FRONTIERS IN CARDIOVASCULAR MEDICINE, 2019, 6

[2] EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update [J].

Agca, R. ;

Heslinga, S. C. ;

Rollefstad, S. ;

Heslinga, M. ;

McInnes, B. ;

Peters, M. J. L. ;

Kvien, T. K. ;

Dougados, M. ;

Radner, H. ;

Atzeni, F. ;

Primdahl, J. ;

Sodergren, A. ;

Jonsson, S. Wallberg ;

van Rompay, J. ;

Zabalan, C. ;

Pedersen, T. R. ;

Jacobsson, L. ;

de Vlam, K. ;

Gonzalez-Gay, M. A. ;

Semb, A. G. ;

Kitas, G. D. ;

Smulders, Y. M. ;

Szekanecz, Z. ;

Sattar, N. ;

Symmons, D. P. M. ;

Nurmohamed, M. T. .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :17-28

[3] 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult [J].

Anderson, Todd J. ;

Gregoire, Jean ;

Pearson, Glen J. ;

Barry, Arden R. ;

Couture, Patrick ;

Dawes, Martin ;

Francis, Gordon A. ;

Genest, Jacques ;

Grover, Steven ;

Gupta, Milan ;

Hegele, Robert A. ;

Lau, David C. ;

Leiter, Lawrence A. ;

Lonn, Eva ;

Mancini, G. B. John ;

McPherson, Ruth ;

Ngui, Daniel ;

Poirier, Paul ;

Sievenpiper, John L. ;

Stone, James A. ;

Thanassoulis, George ;

Ward, Richard .

CANADIAN JOURNAL OF CARDIOLOGY, 2016, 32 (11) :1263-1282

[4]

[Anonymous], CAUS DEATH 2018

[5] Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials [J].

Bhala, N. ;

Emberson, J. ;

Merhi, A. ;

Abramson, S. ;

Arber, N. ;

Baron, J. A. ;

Bombardier, C. ;

Cannon, C. ;

Farkouh, M. E. ;

FitzGerald, G. A. ;

Goss, P. ;

Halls, H. ;

Hawk, E. ;

Hawkey, C. ;

Hennekens, C. ;

Hochberg, M. ;

Holland, L. E. ;

Kearney, P. M. ;

Laine, L. ;

Lanas, A. ;

Lance, P. ;

Laupacis, A. ;

Oates, J. ;

Patrono, C. ;

Schnitzer, T. J. ;

Solomon, S. ;

Tugwell, P. ;

Wilson, K. ;

Wittes, J. ;

Baigent, C. ;

Adelowo, O. ;

Aisen, P. ;

Al-Quorain, A. ;

Altman, R. ;

Bakris, G. ;

Baumgartner, H. ;

Bresee, C. ;

Carducci, M. ;

Chang, D-M. ;

Chou, C-T. ;

Clegg, D. ;

Cudkowicz, M. ;

Doody, L. ;

El Miedany, Y. ;

Falandry, C. ;

Farley, J. ;

Ford, L. ;

GarciLosa, M. ;

Gonzalez-Ortiz, M. ;

Haghighi, M. .

LANCET, 2013, 382 (9894) :769-779

[6] Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia [J].

Bhatt, Deepak L. ;

Steg, P. Gabriel ;

Miller, Michael ;

Brinton, Eliot A. ;

Jacobson, Terry A. ;

Ketchum, Steven B. ;

Doyle, Ralph T., Jr. ;

Juliano, Rebecca A. ;

Jiao, Lixia ;

Granowitz, Craig ;

Tardif, Jean-Claude ;

Ballantyne, Christie M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :11-22

[7] Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein - A randomized placebo-controlled study [J].

Bogaty, P ;

Brophy, JM ;

Noel, M ;

Boyer, L ;

Simard, S ;

Bertrand, F ;

Dagenais, GR .

CIRCULATION, 2004, 110 (08) :934-939

[8] Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT [J].

Bohula, Erin A. ;

Giugliano, Robert P. ;

Cannon, Christopher P. ;

Zhou, Jing ;

Murphy, Sabina A. ;

White, Jennifer A. ;

Tershakovec, Andrew M. ;

Blazing, Michael A. ;

Braunwald, Eugene .

CIRCULATION, 2015, 132 (13) :1224-1233

[9] High serum C-reactive protein level is not an independent predictor for stroke - The Rotterdam Study [J].

Bos, Michiel J. ;

Schipper, C. Maarten A. ;

Koudstaal, Peter J. ;

Witteman, Jacqueline C. M. ;

Hofman, Albert ;

Breteler, Monique M. B. .

CIRCULATION, 2006, 114 (15) :1591-1598

[10] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].

Bresalier, RS ;

Sandler, RS ;

Quan, H ;

Bolognese, JA ;

Oxenius, B ;

Horgan, K ;

Lines, C ;

Riddell, R ;

Morton, D ;

Lanas, A ;

Konstam, MA ;

Baron, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102

← 1 2 3 4 5 6 7 8 9 →